Trial Profile
A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Pfizer
- 10 Dec 2022 Results evaluating the safety and tolerability of rimegepant in adults with cardiovascular (CV) risk factors, presented at the 16th European headache federation COngress
- 13 Jun 2022 According to a Biohaven Pharmaceuticals Media Release, data from this study were presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS)
- 13 Jun 2022 Results published in the Biohaven Pharmaceuticals Media Release